Xcorporeal, Inc. Appoints Kelly J. McCrann as Chairman and Chief Executive Officer

  
    
  
  
    
      Xcorporeal, Inc. (AMEX:XCR) announced today that Kelly J. McCrann has 
      been appointed Chairman and Chief Executive Officer. Mr. McCrann has 
      served as a member of the Company’s Board of 
      Directors since October 2007. Mr. McCrann replaces Daniel S. Goldberger 
      who has been the Company’s acting Chief 
      Executive Officer since February 2008 and Terren S. Peizer, who has been 
      Chairman since the Company’s inception. Mr. 
      Peizer will remain on the Board, and Mr. Goldberger will remain on the 
      Board of the Company’s operating subsidiary.
    
    
      Mr. McCrann is a senior healthcare executive with extensive experience 
      in board governance, strategic leadership, profit and loss management 
      and strategic transactions. He was recently Senior Vice President of 
      DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in 
      the United States, where he was responsible for all home-based renal 
      replacement therapies for the United States’ 
      second largest kidney dialysis provider. Prior to that, Mr. McCrann was 
      the Chief Executive Officer and President of PacifiCare Dental and 
      Vision, Inc. He has held positions of increasing responsibility at 
      Professional Dental Associates, Inc., Coram Healthcare Corporation, 
      HMSS, Inc. and American Medical International. He is a graduate of the 
      Harvard Business School and began his career as a consultant for KPMG 
      and McKinsey & Company.
    
    
      “We are extremely pleased to have Kelly join 
      our experienced management team,” said Mr. 
      Peizer. “We have spent over a year together on 
      the Board of Directors and I’ve gained great 
      confidence in Kelly’s ability to lead the 
      Company through development and commercialization of its hospital 
      hemodialysis machine and The XCR-6 for home hemodialysis.” 
      Mr. Goldberger commented, ”We also thank 
      Terren for his role in founding the Company and helping it in capital 
      formation, and we look forward to his continued role as a member of the 
      Board.”
    
    
      Mr. McCrann stated, “I am truly excited to 
      join Xcorporeal’s management team at a time 
      when the Company’s products are demonstrating 
      the potential competitive advantages anticipated earlier when I began to 
      serve on the Board of Directors. I look forward to bringing my 
      management expertise and industry knowledge to the Company and help to 
      lead further development and eventual commercialization of the Company’s 
      state-of-the-art devices.”
    
    
      About Xcorporeal
    
    
      Xcorporeal, Inc. is a medical device company developing an innovative extra-corporeal 
      platform technology to be used in devices to replace the function of 
      various human organs. The platform leads to three initial products: a 
      Portable Artificial Kidney (PAK) for hospital based Renal Replacement 
      Therapy, the XCR-6 for home hemodialysis, and a Wearable Artificial 
      Kidney (WAK) for continuous ambulatory hemodialysis.
    
    
      For the hospital market, Xcorporeal is developing a portable, 
      multi-functional renal replacement device that will offer cost-effective 
      therapy for those patients suffering from Acute Renal Failure, which 
      causes a rapid decline in kidney function. In the U.S., the disease 
      affects more than 200,000 patients annually with a mortality rate 
      approaching 50%, according to a study published in the Clinical Journal 
      of American Society of Nephrology in 2006. The Company has completed a 
      functional prototype of the product, which is currently undergoing bench 
      testing, and anticipates submitting 510(k) filings, for the device and 
      attendant disposable components, with the Food and Drug Administration 
      (FDA) during 2009.
    
    
      The Company also plans to commercialize the XCR-6, a home hemodialysis 
      device, for the chronic End Stage Renal Disease (ESRD) market, comprised 
      of patients in whom the kidneys have ceased to function. The Company’s 
      devices are intended to combine the best attributes of currently 
      marketed home hemodialysis machines to offer patients convenient, 
      durable and truly portable treatments at home. The Company believes its 
      devices will provide a cost-effective alternative to current home 
      treatment modalities, due to their ability to offer hemodialysis without 
      the need for large quantities of dialysate fluid or purified water. The 
      Company has also completed a functional prototype of the XCR-6, which is 
      currently undergoing bench testing, and anticipates submitting a 510(k) 
      with the FDA during 2010.
    
    
      The Company’s WAK is also a device for the 
      chronic treatment of ESRD. The Company has successfully demonstrated a 
      prototype system that weighs less than 6 kg., is battery operated, and 
      can be worn by an ambulatory patient. This miniature, wearable device is 
      intended to enable continuous (up to 24 hours × 
      7 days per week) renal replacement therapy at home. Increasing dialysis 
      time has previously been shown to reduce morbidity and improve quality 
      of life of ESRD patients. The WAK has been featured in articles written 
      by the Los Angeles Times, The Lancet, Kidney International, and various 
      other medical periodicals.
    
    
      Additional Company information may be found on the Internet at: www.xcorporeal.com.
    
    
      Forward-Looking Statements
    
    
      Except for statements of historical fact, the matters discussed in this 
      press release are forward looking and made pursuant to the Safe Harbor 
      provisions of the Private Securities Litigation Reform Act of 1995. 
      These forward-looking statements reflect numerous assumptions and 
      involve a variety of risks and uncertainties, many of which are beyond 
      the company's control that may cause actual results to differ materially 
      from stated expectations. These risk factors include, among others, 
      limited operating history, difficulty in developing, exploiting and 
      protecting proprietary technologies, the risk that our technology may 
      not be effective, uncertainty as to the outcome of arbitration and legal 
      proceedings, intense competition and substantial regulation in the 
      medical device industry; and additional risks factors as discussed in 
      the reports filed by the Company with the Securities and Exchange 
      Commission, which are available on its website at http://www.sec.gov.